Open-House Rebate Agreements (aut idem) for Pharmaceutical Products
Notice title: Open-House-Rabattverträge 2026-16 (aut idem)
Open-House rebate agreements according to § 130a Abs. 8 SGB V for pharmaceutical products: active ingredients, active ingredient combinations, dosage forms, strengths, or finished medicinal products, including Carbamazepine (RET, excluding 150 mg), Ciclosporin (WKA, excluding 10 mg), Everolimus (ATC: L04AH02; TAB), Levothyroxine sodium (TAB), Levothyroxine sodium (TKA), Levothyroxine sodium/Potassium iodide (excluding 0.05 mg/0.0981 mg, 0.075 mg/0.0981 mg, 0.1 mg/0.0981 mg), Levothyroxine sodium/Liothyronine, Tacrolimus (HKP), Tacrolimus (REK), Valproic acid and/or Valproate (RET).
Never miss a tender again
We send you 3 current matches that fit your company.
Tender documents
- Portal — LOT-0001NON-RESTRICTED-DOCUMENT
- TED HTML — 657556-2026HTML
- TED PDF — 657556-2026PDF
- TED XML — 657556-2026XML
Unlock documents for free
Enter your email address. If you confirm, we will also send you 3 similar tenders.
Lots (10)
- LOT-0001Carbamazepin (RET, ausgenommen 150 mg)
- LOT-0002Ciclosporin (WKA, ausgenommen 10 mg)
- LOT-0003Everolimus (ATC: L04AH02; TAB)
- LOT-0004Levothyroxin natrium (TAB)
- LOT-0005Levothyroxin natrium (TKA)
- LOT-0006Levothyroxin natrium/Kaliumiodid (ausgenommen 0,05 mg/0,0981 mg, 0,075 mg/0,0981 mg, 0,1 mg/0,0981 mg)
- LOT-0007Levothyroxin natrium/Liothyronin
- LOT-0008Tacrolimus (HKP)
- LOT-0009Tacrolimus (REK)
- LOT-0010Valproinsäure und/oder Valproat (RET)